Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. - Wikidata - wikimedia - TriplyDB

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

http://www.wikidata.org/entity/Q34898980

about

Treatment of Cancer Pain by Targeting Cytokines ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Growth factor and signaling pathways and their relevance to prostate cancer therapeutics Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Recent advances in bone-targeted therapies of metastatic prostate cancer Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231 Bone-targeting agents in prostate cancer.The best of both worlds - managing the cancer, saving the bone.Mechanism of cancer pain.Emerging treatment options for patients with castration-resistant prostate cancer.Endothelin B receptor, a new target in cancer immune therapy.Anti-endothelin drugs in solid tumors.Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.Emerging therapies in metastatic bone pain.Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion.Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse?Targeted therapy in prostate cancer.Role of the endothelin axis and its antagonists in the treatment of cancer Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.Castration-resistant prostate cancer: new science and therapeutic prospects.Health-related quality of life and cancer clinical trials.Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.The PCa Tumor Microenvironment.A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Emerging targeted therapies for castration-resistant prostate cancer.Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).Management of bone metastases in refractory prostate cancer--role of denosumab.Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells New and emerging therapies for bone metastases in genitourinary cancers.Unmet needs in the prediction and detection of metastases in prostate cancer.Perspectives on treatment of metastatic castration-resistant prostate cancer.

P2860

Q26779917-8F8F4C16-25A4-4DE6-A97F-E15B99769B73 Q26796568-A57BBA65-EC0F-4791-8D74-7E0803561745 Q26827975-76669037-6EAB-4FB3-A501-98D53DF8B511 Q27021268-8B3C7570-088F-4E77-A4E0-03EE5B89FC20 Q28294857-20FA58F7-0E9A-4807-8A75-F33FA753FFC2 Q30239808-814B24F9-295F-4AC6-B304-44EE43F84CCF Q33642278-DFC50764-B31A-43AA-84DE-1463C33B21B2 Q33703763-5EF77033-2C7B-4647-9B52-AC714CCDA9F6 Q33756117-940175CF-4263-434B-A174-57706EF20F70 Q33864723-B977D804-AE5F-422E-B9F9-AE876D2394D8 Q33920055-4C12742B-C505-4761-AA5B-C308F8D9F747 Q33953901-3AA562C9-2AAC-49C0-A5CB-69CB24CF0CDB Q33958519-81BC512E-589F-40BF-8011-D76C2F1F1984 Q33960710-8303777D-F00C-436B-9C3A-EAE9A14E16FC Q34021011-5908C571-6C5F-4A59-AFFC-7D652B60BAC4 Q34157915-B6409E84-A050-484F-A06F-896269A74C9A Q34161050-92A917EC-0517-40AC-95E9-0FE7CFCEEB65 Q34182919-44B60371-D52C-4978-A379-3EB84B429D48 Q34406622-0322E054-55AD-40EC-9D8D-36CF4990E833 Q34502911-3E0C2D2A-1D89-4B44-8AA9-97A0D82F8929 Q34509741-5AD8D71A-CCBF-467D-ACC0-8C1177C0027E Q34634763-E27B7A13-D1DC-41E7-B5D7-0BC5BA210C4D Q34919570-B76F11CF-2898-4542-9BC1-7CC33584BCD7 Q35048211-FB99C833-E9DA-4D56-B8E6-77B2B361FCCF Q35076264-9DDF98AC-B7D6-475C-BFDA-3852359B925E Q35076356-A6AA38A8-A0AA-471C-A6BD-49D2549D7A8E Q35218871-44EBBCFF-E121-4BC0-9E3F-0C764EDDF26E Q35555303-0D56063A-E918-4C1D-A3E4-054225F3F7A6 Q35584269-837E689A-F036-4A13-A8BF-5BA5645FF878 Q35603143-EE254CE6-7361-4EBC-8471-3EC8CD76B72D Q35698539-9A786FD4-4F80-4BD7-B0E2-072ACF137DB9 Q35879087-2C88A91A-D9C2-4207-B6BD-0A5A243E05CB Q35999255-4A9A1B8F-6538-4258-9A03-96CC79414A30 Q36056197-CD905FC0-F5F7-42D3-A984-7BC64AE9EAAF Q36260345-8CE07FB7-83BA-4AFD-9C24-5BA9DE51F852 Q36283689-D6703A4B-613A-4D3E-B2E3-F31DDEFEFAB7 Q36608738-49EDC958-C02D-4711-9B83-E83A7114986E Q36866291-4BDD8443-6F70-4A92-8E66-7CDFAE8CAEE4 Q36871680-CA224AFC-73A4-4E78-B047-4B1999BA110B Q36871685-EB947F3D-B7F4-4950-8D23-D1942365CB0B

P2860

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

http://www.wikidata.org/entity/Q34898980

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@ast

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@en

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@nl

type

label

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@ast

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@en

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@nl

prefLabel

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@ast

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@en

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@nl

P1433

Q34898980-FCDF43D9-8BE3-49C3-8EC1-612CD90F5FCD

P1476

Q34898980-933163F9-DA91-410F-ADFE-D140786982CE

P2093

Q34898980-1E88D9C5-9A10-4889-9C2E-EF51509D3396

Q34898980-3A1F4A6D-DBCA-488D-97C5-B13677065768

Q34898980-44700BD1-B7F7-4ACC-8D11-79490537D119

Q34898980-53816609-4A98-457C-93BB-A5C508C014F6

Q34898980-8134E724-FC86-49F2-8AA9-EC614BC261BF

Q34898980-82B27261-F8F8-44E8-8842-EFF4730A287A

Q34898980-96B6FA66-3C94-4D0C-9419-8CB97E90D16F

Q34898980-B86A4C2F-239D-4F5C-87EF-39E94654246F

Q34898980-F532111F-6342-42FA-8105-D25BB9241D11

Q34898980-F78A0D84-2562-4F36-B61F-A1BDEE50AAA9

P2860

Q34898980-16DFE259-8B9D-473F-BC0F-C5B4D47D8C13

Q34898980-1B1168FF-BF5E-4C99-BA41-D90464121CB8

Q34898980-25766EEF-94DC-4E6E-A798-F579C8B399D0

Q34898980-27196319-383F-4F5B-9679-DA3CCA271AE2

Q34898980-41100A91-5686-484E-AD44-7EC5962F888F

Q34898980-433D8393-A20E-4DA7-8DDF-92A0AEA2CC08

Q34898980-44157FFB-248F-43CE-99EA-DC802A3955FA

Q34898980-54B4C967-5117-476C-A98C-628BBC62757C

Q34898980-6AA20A9E-C9F6-4F9E-9D2F-525426A74776

Q34898980-7239B800-63B8-487A-8706-808D650FDC30

P304

Q34898980-2BCB5FAF-CF1E-48EA-97B7-3CE708141D3F

P31

Q34898980-250D25B6-4696-469B-BD47-763F035518F5

P356

Q34898980-B7BAE7F9-0514-4C8E-86B2-BED7EAF8E1AE

P407

Q34898980-13E40FC1-914B-4120-B633-A687A0F9D816

P433

Q34898980-9D441DD4-9AC2-4970-8DF7-38F6C18B670E

P478

Q34898980-0DEABA09-1A75-4982-A682-F49A995DB678

P577

Q34898980-1BE917F4-15C4-4011-8381-7F8C26F42BFF

P5875

Q34898980-357B68F7-2C7C-4911-BF53-AD35931E27AC

P698

Q34898980-E60981A7-C0BA-4832-AD14-64CE539E47A9

P921

Q34898980-DF11C6E6-C99A-41C3-BF31-F02819C6449B

Q34898980-E2AD057E-04EE-4061-829A-0FB7D482FC80

P932

Q34898980-41699D08-964A-4FFB-93B1-52641C00AEB0

P356

P1433

P1476

Phase 3, randomized, controlle ...... ne-refractory prostate cancer.

@en

P2093

Atrasentan Phase 3 Study Group

http://www.w3.org/2001/XMLSchema#string

Claude C Schulman

http://www.w3.org/2001/XMLSchema#string

Darryl J Sleep

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Jiang Qian

http://www.w3.org/2001/XMLSchema#string

Joel B Nelson

http://www.w3.org/2001/XMLSchema#string

Joseph L Chin

http://www.w3.org/2001/XMLSchema#string

Joyce Steinberg

http://www.w3.org/2001/XMLSchema#string

Michael Carducci

http://www.w3.org/2001/XMLSchema#string

William Love

http://www.w3.org/2001/XMLSchema#string

P2860

Endothelin receptors as novel targets in tumor therapy

Global cancer statistics, 2002

The endothelin axis: emerging role in cancer

Cancer statistics, 2007

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Role of endothelin-1 in osteoblastic bone metastases.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?

P304

2478-2487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23864

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23250754

http://www.w3.org/2001/XMLSchema#string

P698

18785254

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

3085548

http://www.w3.org/2001/XMLSchema#string